Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Tuesday 27 February 2024 6:17 am  |  Updated:  Tuesday 27 February 2024 10:13 am

Meet the women building a new way to deal with cancer

By: Jennifer Sieg

SME Correspondent

Add as a preferred source on Google
Perci Health co-founders Morgan Fitzsimons and Kelly McCabe realised there was a gap that needed filling within the healthcare sector.
Perci Health co-founders Morgan Fitzsimons and Kelly McCabe realised there was a gap that needed filling within the healthcare sector.

The latest in our Ambition A.M. series sees Jennifer Sieg speak to the women behind a virtual cancer support centre.

A pot of coffee wasn’t the only thing brewing in the background the day Kelly McCabe and Morgan Fitzsimons sat down to chat at their local cafe. “There’s a thing…” Fitzsimons recalled hearing her colleague say before being presented with an out-of-the-blue business opportunity.

As one ‘thing’ led to another, the now-co-founders of Perci Health – a virtual cancer support clinic – quickly realised the difference in their skill sets would soon become their formula for success. Especially when the mission is to leverage technology in a way that easily connects patients with human practitioners.

The two agreed the past three years have been worthwhile – thanks to the resilience that comes with “throwing spaghetti at the wall” – but launching a paid-for healthcare platform in Britain wasn’t an easy task.

The formula for success

Disruptive innovation often comes when two entrepreneurs are committed to making a change. At least, that’s what happened when Fitzsimons and McCabe realised there was a gap that needed filling within the healthcare sector.

McCabe, who spent over a decade working in the NHS and private sector, spotted the need for digital innovation when she noticed a growing number of cancer ‘survivors’ – a word Fitzsimons admitted not everyone likes – still seeking guidance after their treatments ended.

But, like any new business venture, the idea to provide accessible healthcare options to these patients could only go so far without a strong plan in motion.

McCabe knew she needed Fitzsimons’ digital-led background to make it work. “Leaning too heavily into clinical without thinking about the member experience, or building a great product but without the clinical know-how can all be disastrous,” McCabe said.

I believe we’ve got the perfect balance, further complemented now by our growing team.

Kelly McCabe

Fitzsimons agreed as she said the two often laugh over how she has personally “gotten really good at getting people to buy stuff they don’t need” throughout her previous digital marketing roles within online retailers, including a full three years at Asos.

Now using what she called her “evil skills for good,” Fitzsimons said much of what Perci Health had as a barrier from the start was the need to educate others on what they were trying to achieve – and in this case, what patients needed.

“There’s an assumption that this is being taken care of somewhere, everyone assumes that someone else is doing it,” Fitzsimons said.

Read more

Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

“So you talk to private healthcare, and they’re like ‘oh, don’t the NHS do it?’ and then you talk to the NHS and they’re like ‘don’t charities do it?’ and then you talk to charities, and they’re like ‘don’t GPs do it?’” she continued.

Fitzsimons considered much of this back-and-forth to be like a game of tennis, but it wasn’t until they spoke with the patients directly that they realised they were the first to offer this post-treatment guidance.

Despite inevitable challenges on the horizon, the two worked their way through to “regroup, regather and pivot,” Fitzsimons said while hand-gesturing a bumpy ride.

Leveraging technology

With little hesitation, Fitzsimons said the biggest challenge to date was setting out to build a paid-for healthcare system in a country where healthcare access is available for free.

“Who is going to pay for this is the hardest thing,” she added. “Obviously we found some routes to market, and I guess that’s my bread and butter, but healthcare is a specific challenge.”

The ultimate goal, Fitzsimons said, is to give everyone affordable access to the healthcare they need – hopefully through a future partnership with the NHS – but to do that they need to get their feet off the ground, first.

“Working out who is willing to pay for this care so that the person with cancer doesn’t have to and so we can reach the scale we want to has been challenging,” McCabe added.

So far, Perci Health has partnered with large insurers – including Healix Health and L&G – to allow each insurer’s patients free access to their platform’s support.

These continued achievements and partnerships throughout the hardships help make way for Perci Health’s “longevity,” Fitzsimons continued.

“It’s the best start to Perci,” she admitted. “If we can do it here we can do it anywhere.”

Indeed, the two aren’t the only ones confident in their abilities, as Perci Health closed its most recent seed funding round of £3.4m by Octopus Ventures with plans to grow their technological roadmap, and team, even more

Read more

Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News
  • Life&Style

Categories

  • Entrepreneurship
  • Business

Related Topics

  • Health

Trending Articles

  • Harry Styles at Wembley Stadium review: running through the grief

  • Nottingham Forest owner Marinakis announces £210m stadium plans

  • I’ve taken the best train trips in the world. Here are my 5 favourites

  • Natwest boss becomes latest City figure caught in AI social media scam

  • Nothing fails to file accounts months after dissolution threat

More from City PM

  • Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

    Business Wire
  • Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer

    Business Wire
  • People named Mark called upon to raise money at London charity golf day

    Sport Business
    Breaking news concept with digital globe and newspaper headlines on a blue background, representing global journalism.
  • Why Richard Harpin sold half of homeServe for half a million pounds — and what he’d do differently

    Business
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • Elevate founder Julia Baldet: Hospitality is brutal, but I don’t regret leaving finance

    Opinion
    Julia Baldet presenting at Elevate conference, discussing business strategies in a professional setting.
  • IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

    Business Wire
  • Burnham refuses to rule out ‘exit tax’ as founders warn of wealth exodus

    Politics
    Andy Burnham with Labour MPs discussing party strategy at a conference setting

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy